S2206 Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Br

Brief description of study

In this study, the study team wants to find out if adding a medicine called durvalumab to the usual chemotherapy for breast cancer helps patients do better. The study team will compare two groups: one getting regular chemotherapy alone, and the other getting the same chemotherapy but with durvalumab at the same time. They are checking if patients stay free of breast cancer events, how well the treatments work, and if there are any side effects from treatment. Also, the study team is interested in how patients feel during and after treatment, especially looking at things like tiredness of a patient and overall physical health. The study team will also save some samples for future studies. The goal is to understand if this new approach can improve outcomes for patients with breast cancer.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.